26/09/2024 – AB Science today provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement Download PDF Post navigationPreviousPrevious post:AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024NextNext post:AB Science announces the success of a 5.0 million euros capital increaseRelated PostsSummary of the webcast held on December 16, 2024December 17, 2024AB Science webcast of December 16, 2024December 16, 2024Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CETDecember 11, 2024AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell diseaseOctober 28, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024Revenues for the first half of 2024 and update on AB Science’s activitiesOctober 10, 2024
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell diseaseOctober 28, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024
